Mitsubishi Gas Chemical Company, Inc. Overview
Mitsubishi Gas Chemical is a mid-cap Japanese chemical company that has spent four decades migrating from natural-gas-derived commodity chemistry (methanol, ammonia derivatives, xylenes) toward proprietary functional and electronic materials. It is a Mitsubishi-group company but not a subsidiary of any Mitsubishi entity; its share register is dominated by trust banks, life insurers and agricultural cooperatives. Its crown jewels are BT (bismaleimide-triazine) laminate materials for semiconductor package substrates, in which MGC is widely regarded as the category originator, the fast-growing OPE® substrate material for AI servers, ultra-pure hydrogen peroxide and functional chemicals for semiconductor fabs, optical resin polymers for smartphone camera lenses, and MXDA-based specialty aromatics. These sit alongside a cyclical but strategically important equity-accounted methanol network (Saudi Arabia, Brunei, Venezuela, Trinidad & Tobago). In FY2025 MGC booked ¥78.4bn of impairments and its first net loss since FY2012, triggering a sharper portfolio restructuring under the "Grow UP 2026" plan.
What the company does — company's own description (paraphrased from Yuho FY2025)
MGC organizes its group into two reportable segments plus "Other". The Green Energy & Chemicals Division (GEC) manufactures and sells methanol, methanol- and ammonia-based chemicals, life-science products, general-purpose and specialty aromatic chemicals, foamed plastics (through equity affiliate JSP) and electricity. The Functional Chemicals Division (FC) manufactures and sells inorganic chemicals (hydrogen peroxide and semiconductor-grade chemicals), engineering plastics, optical materials, electronic materials and oxygen absorbers. "Other" captures purchased-goods trading not attributed to either segment. The company's mission statement is "creating value to share with society", and its 2030 Vision centres on chemistry-driven social value and sustainable growth.
Business model and revenue model
| Revenue / income stream | Nature | Where it shows up | Materiality |
|---|---|---|---|
| Product sales | Chemicals, resins, laminates, consumables sold under supply contracts and spot | Net sales | c.100% of net sales |
| Equity-method income | Share of profit of methanol JVs (Saudi Arabia, Brunei, Venezuela, Trinidad & Tobago), JSP, Korea Engineering Plastics, etc. | Non-operating income (ordinary profit) | ¥17.5bn FY2022, –¥5.7bn FY2023, ¥11.0bn FY2024, ¥1.5bn FY2025 |
| Technology licensing | Non-exclusive licences for methanol/DME technology (METOR, Brunei Methanol, Caribbean Gas Chemical); PC technology licence to Shanghai subsidiary with running royalty | Royalty/one-time fees; largely intra-group or embedded in equity income | — |
| Electricity / energy | LNG-fired and geothermal power sales, natural gas, iodine | Net sales (GEC) | — |
| Contract manufacturing | Antibody drug CDMO via JV Cultivecs (1,000L and 2,000L bioreactors) | Equity/affiliate | — |
MGC's revenue is overwhelmingly product sales (B2B chemicals and materials). Material secondary income streams are:
There is no subscription revenue. The business model therefore combines (i) asset-heavy commodity chemistry whose profit is highly sensitive to methanol and polycarbonate spreads, with (ii) IP-protected specialty materials sold on specification into qualified customer processes (substrate makers, fabs, lens makers) where switching costs are high.
Value-chain position
Upstream / feedstock: Owns natural gas and iodine production in Niigata (Toho Earthtech), geothermal stakes (Yuzawa Geothermal, Appi Geothermal), and equity in overseas gas-to-methanol plants. Buys xylene, energy and raw materials externally (Yuho risk section).
Midstream: Methanol, ammonia derivatives (methylamines, DME, MMA products), xylene separation/isomerization (own technology since 1968), MXDA, aromatic aldehydes, polyols, hydrogen peroxide.
Downstream materials: BT laminate and prepreg materials, OPE®, ultra-pure H2O2 and HBC functional chemicals, Iupizeta EP optical polymers, lens monomers, Iupilon PC and Iupital POM, AGELESS oxygen absorbers.
- MGC rarely sells to consumers; nearly all customers are industrial converters.
Customer types and end-markets
| End-market | Products | Customer type |
|---|---|---|
| Semiconductors / ICT | BT materials, OPE®, ultra-pure H2O2, HBC chemicals, LE SHEET drilling entry boards | IC substrate makers, PCB makers, semiconductor fabs (Japan, Taiwan, Korea, US, Singapore, China) |
| Smartphones / optics / AR-VR / automotive sensors | Iupizeta EP optical resin polymers, spectacle lens monomers | Camera-lens molders, ophthalmic lens makers |
| Automotive / mobility | MXDA derivatives, MX-Nylon, LEXTER bio-polyamide, PC, POM, mPPE | Tier-1 component makers, coatings/epoxy formulators |
| Packaging / food / pharma | MX-Nylon barrier resins, AGELESS oxygen absorbers, special polyester (baby bottles) | Food and pharma packagers |
| Chemicals / coatings | Methanol, formaldehyde, MMA products, polyols, PIA | Chemical companies, paint makers (e.g., Kansai Paint is a disclosed customer) |
| Energy / environment | LNG power, geothermal, iodine (incl. perovskite-solar derivatives), methanol bunkering | Utilities, shipping, specialty chemical users |
| Healthcare / food | BioPQQ, SAMe yeast, spermidine yeast, lactic acid bacteria, antibody CDMO | Supplement makers, biopharma |
Independent characterization
MGC is best understood as two companies under one roof. The FC segment (61% of FY2025 external sales but c.95% of FY2025 segment ordinary profit) is a quality specialty-materials franchise geared to semiconductor packaging and AI-server build-outs. The GEC segment (38% of sales) is a methanol-and-aromatics complex whose earnings swing violently with commodity prices and equity-affiliate results: GEC ordinary profit fell from ¥20.5bn in FY2024 to ¥3.9bn in FY2025 after the Trinidad affiliate impairment and MXDA price erosion. The market valuation (P/B c.1.1x) still prices MGC closer to a diversified Japanese chemical company than to a semiconductor-materials pure play; the investment debate is about whether portfolio restructuring can close that gap.
Strategy
Stated strategy — "Grow UP 2026" (FY2024–FY2026)
Two goals, each with three measures (Yuho FY2025):
Goal 1 — Strengthen business portfolio resilience
-
Focus on "Uniqueness & Presence" (U&P) businesses — formerly "differentiated businesses", redefined as businesses that excel on growth potential, ability to win and sustainability (expectation, economic value, social value).
-
Create new value through innovation — target domains ICT, mobility, and medical/food.
-
Restructure "priority management" businesses — polycarbonate, xylene chain/MXDA, formalin and other underperformers; a President-led "Business Portfolio Resilience Task Team" was formed in FY2025.
Goal 2 — Promote sustainability management
-
Accelerate carbon neutrality (Carbopath™ circular methanol, GHG reduction, Sharebeing products).
-
Enhance human-capital management.
-
Materiality management.
Financial targets (FY2026, final plan year) vs. delivery
| Metric | FY2024 actual | FY2025 actual | FY2026 company guidance (Aug 2026) | FY2026 plan target |
|---|---|---|---|---|
| Net sales (¥bn) | 773.5 | 738.2 | 860.0 | 850.0 |
| Operating profit (¥bn) | 50.8 | 45.2 | 71.0 | 85.0 |
| Operating margin (%) | 6.6 | 6.1 | 8.3 | ≥10 |
| Ordinary profit (¥bn) | 60.3 | 51.9 | 79.0 | 95.0 |
| EBITDA, company definition (¥bn) | — | — | — | 150.0 |
| ROE (%) | 6.9 | -6.1 | c.8.5 (analyst estimate from guidance) | ≥9 |
| ROIC (%) | 6.4 | 3.2 | — | ≥8 |
Plan assumptions: ¥135/US$ and Dubai crude US$80/bbl. Long-term vision: net sales of ¥1.2 trillion by 2030 (2025 Integrated Report summary). Sharebeing (environment-contributing products) sales target: ¥500bn by FY2030.
Capital allocation policy
Shareholder returns: total payout ratio of 50% (including buybacks) as medium-term guide; progressive dividend policy (avoid cuts unless financial soundness is threatened); DOE target 3.0%.
Buybacks: opportunistic (¥10bn in FY2023, ¥15bn in FY2024; none in FY2025).
Cross-shareholdings: annual board review; FY2025 sales of seven listed holdings for ¥6.1bn (e.g., Iwatani fully sold; Mitsubishi Corporation stake cut from 613,200 to 10,200 shares).
Strategic initiatives register (last c.24 months)
| Date | Initiative | Type | Detail / status |
|---|---|---|---|
| FY2024–FY2025 | BT materials capacity doubling at MGC Electrotechno (Thailand) | Growth capex | Completed Nov 2025 |
| FY2024–FY2025 | Semiconductor chemicals capacity expansion in Taiwan | Growth capex | Completed; fixed costs weighed on FY2025; impairment recorded at Taiwan subsidiary |
| FY2024–FY2025 | Electronic chemicals ("EL chemicals") projects in Japan and overseas | Growth capex | Returns delayed per management (Jul 2026 briefing) |
| FY2025 | OPE® new manufacturing base | Growth | Under consideration |
| FY2025–FY2026 | New lens-monomer plant | Growth | In progress |
| FY2025–FY2026 | Iodine capacity expansion | Growth | Planned |
| Sep 2025 → Feb 2026 | Netherlands MXDA plant (MSCN) | Restructuring | Suspended, impaired ¥50.2bn, discontinued; removal by end-2029 |
| Mar 2026 | Kashima PC plant (120kt/yr) closure | Restructuring | Operations end Mar 2028; Iupizeta EP unaffected |
| FY2024–FY2025 | Exit from ortho-xylene, phthalic anhydride, plasticizers | Restructuring | Production stopped |
| FY2025 | PC sheet/film site consolidation | Restructuring | Completed |
| FY2025 | Structural reforms incl. asset sales | Cost/portfolio | c.¥15bn earnings improvement claimed for FY2025 (Jul 2026 briefing) |
| Nov 2025 | Long-term offtake of c.1 mtpa ultra-low-carbon methanol from Pacifico Mexinol (Transition Industries) from 2029 | Decarbonization | First large-scale procurement under Carbopath |
| FY2025 | MoU with TRE Holdings on Japan's first commercial-scale green methanol from woody biomass and waste | Decarbonization | MoU |
| FY2025 | Methanol dual-fuel carrier "Dai-7 Kozan Maru" (long-term charter from MOL) delivered; ship-to-ship methanol bunkering at Yokohama anchorage | Decarbonization / logistics | Completed |
| FY2025 | Equity investment in Gold Hydrogen Ltd (7.14m shares) | New business (natural hydrogen) | Completed |
| FY2025 | Hiratsuka PR-SHIPS research building | Innovation | Completed |
| FY2025 | MPS device co-development with Ehime University; NEDO international geothermal reservoir research | Innovation | Agreements concluded |
| Ongoing | DX: in-house ML tool "MLAB", supercomputer expansion, IP landscaping | Productivity | Deployed group-wide |
| Ongoing | Internal carbon price ¥10,000/t-CO2 for capex decisions | ESG | In force |
Products & Services
Launch years, specifications and pricing are generally not disclosed by MGC; they are marked accordingly. Pricing for all products is B2B contract/spot pricing; no list prices are published.
Green Energy & Chemicals Division
| Product / brand | Description & capabilities | Target customer | Launch / latest | Pricing model |
|---|---|---|---|---|
| Methanol (domestic production + JV offtake) | Core C1 chemical; produced historically in Niigata and via overseas JVs (Saudi Arabia, Brunei, Venezuela, Trinidad & Tobago). MGC holds proprietary synthesis catalyst and process technology licensed to JVs | Chemical producers, formaldehyde/MMA makers, fuel and shipping (bunkering) | Since 1952 (domestic) | Market-linked (Asian contract/spot) |
| Carbopath™ | Circular-carbon methanol platform; methanol made from CO2, waste plastics, digestion gas, biomass; pilot at Niigata | Decarbonizing chemical, shipping and energy users | Branding launched c.2023 | — |
| Ultra-low-carbon methanol offtake | c.1 million t/yr from Transition Industries' Pacifico Mexinol project (Mexico), from 2029 | Same | Agreement 6 Nov 2025 | Long-term SPA; terms not disclosed |
| Ammonia, methylamines, DME | Derivatives of methanol and ammonia | Chemical, agrochemical, aerosol, fuel users | Long-established | Contract |
| MMA products (methacrylates) | Methyl methacrylate-related derivatives; volume growth in FY2025 | Acrylic resin, coating makers | Long-established | Contract/market |
| Formalin / formaldehyde (MGC Woodchem) | Formaldehyde and stabilizers; sales functions transferred to subsidiary 2023–2024 | Resin, wood adhesive makers | Restructured 2023–2024 | Contract |
| Polyols | Specialty polyols from formaldehyde chemistry | Coatings, resins | Long-established | Contract |
| MXDA (meta-xylenediamine) | Proprietary aromatic diamine used as epoxy curing agent, isocyanate and polyamide feedstock; MGC is the historic global leader. European plant project cancelled Feb 2026 | Coatings, composites, nylon makers | Long-established | Contract; under price pressure |
| 1,3-BAC and related derivatives | Hydrogenated MXDA derivative (curing agents, isocyanates) | Coatings, optical resin makers | — | Contract |
| Aromatic aldehydes | Fragrance intermediates and resin additives | Fragrance houses, polymer additive makers | — | Contract |
| High-purity isophthalic acid (PIA), meta-xylene | From xylene separation at Mizushima; ortho-xylene chain exited | PET/resin producers | Since 1968 (xylene separation) | Market-linked |
| MX-Nylon | Gas-barrier polyamide (MXD6) for packaging and engineering applications | Packaging and auto component makers | Long-established | Contract |
| LEXTER™ | Bio-based polyamide; growing in automotive and electronic parts | Auto/electronic component molders | Recent; expanding | Contract |
| Reny™ | High-performance reinforced polyamide (MXD6-based) | Precision parts molders | Long-established | Contract |
| Special polyester | High-heat transparent polyester; adopted in baby bottles | Consumer goods molders | — | Contract |
| Cyanate esters | High-performance thermoset raw material for composites | Composite makers | — | Contract |
| Transparent polyimide (Neopulim™) | Solvent-soluble, transparent, fully fluorine-free polyimide varnish | Display/flexible device makers | — | Contract |
| Thermoplastic polyimide | High heat resistance, low dielectric, good moldability | Electronics | — | Contract |
| ENDUREDGE™ prepregs | FRP prepregs using MGC resins, developed mainly for the US market | Aerospace/industrial composite users | — | Contract |
| TETRAD™ epoxy | Polyfunctional epoxy resins | Composite, electronics | Long-established | Contract |
| Natural gas & iodine (Toho Earthtech) | Water-soluble natural gas in Niigata with high iodine content; iodine capacity expansion planned; iodine derivatives for perovskite solar cells under development | Utilities, iodine/pharma/electronics users | Long-established | Market-linked |
| LNG power, geothermal power | LNG-fired generation; geothermal stakes (Yuzawa, Appi) | Grid / utilities | Ongoing | Power tariffs |
| CCS | Study of CCS in depleted oil/gas fields | Industrial emitters | Development | — |
| BioPQQ™ (pyrroloquinoline quinone) | Fermentation-derived anti-ageing supplement ingredient | Supplement makers | Long-established | Contract |
| SAMe-containing dried yeast; spermidine-containing yeast; lactic acid bacteria | Nutritional ingredients | Supplement makers | — | Contract |
| Antibody CDMO (Cultivecs JV) | Contract manufacturing of investigational and API antibodies in 1,000L/2,000L tanks | Biopharma | Operating | Contract |
| Foamed plastics (JSP, equity method) | ARPRO and other bead foams | Auto, packaging | JSP equity-accounted since FY2023 | — |
Functional Chemicals Division
| Product / brand | Description & capabilities | Target customer | Launch / latest | Pricing model |
|---|---|---|---|---|
| Hydrogen peroxide (industrial) | Produced since 1978 at Kashima; also overseas (Indonesia affiliate PT Peroksida Indonesia Pratama) | Pulp & paper, chemical, environmental users | 1,978 | Contract |
| Persulfates | Produced at Yamakita | Electronics, polymerization | Long-established | Contract |
| Ultra-pure hydrogen peroxide (ELM series) | Semiconductor-grade wet chemical; multi-site supply: Japan, US (Arizona, Oregon, Texas), Singapore, Korea, Taiwan, China | Semiconductor fabs | Since 1990s (US 1995) | Contract, often long-term |
| Functional chemicals (HBC) and chemical polishing liquids | Front-end to back-end process chemicals; new grades developed globally | Fabs, OSATs | Ongoing | Contract |
| Iupilon™ polycarbonate | General and specialty PC (flame-retardant, low-impurity). Kashima 120kt/yr plant to close March 2028; supply shifting to overseas sites (Shanghai, Thailand) | Electrical/electronics, auto, sheet | Long-established | Market-linked |
| PC sheet & film (MGC Filsheet) | Hard-coat thermoforming film, optical films; production sites consolidated | Display, auto interior, signage | Restructured FY2025 | Contract |
| CO2-based PC intermediate | NEDO Green Innovation Fund project to make PC from CO2 | — | Development | — |
| Iupital™ polyacetal (POM) | Via Global Polyacetal, Thai Polyacetal, Korea Polyacetal and Korea Engineering Plastics JV with Celanese | Auto, electronics molders | Long-established | Market-linked |
| Iupiace™ / LEMALLOY™ modified PPE | Engineering alloys | Electrical/auto | Long-established | Contract |
| MEP (Mitsubishi Engineering-Plastics, 75%) | Sales JV with Mitsubishi Chemical for engineering plastics | Same | Consolidated Apr 2023 | — |
| Iupizeta™ EP optical resin polymer | High-refractive-index optical resin for smartphone camera lenses; expanding to automotive, AR/VR and sensors; post-consumer recycling technology established with customers. Excluded from Kashima PC closure | Lens molders | Latest grades ongoing | Contract |
| Spectacle lens monomers | High-index monomers produced at Naniwa and Yokkaichi; bio-mass lens monomer adopted by a major customer; new lens-monomer plant planned/under way | Ophthalmic lens makers | Ongoing | Contract |
| BT materials | Bismaleimide-triazine copper-clad laminates and prepregs for semiconductor package substrates (memory and logic); dual supply from MGC Electrotechno (Shirakawa, Japan) and MGC Electrotechno (Thailand); Thai capacity doubled (completed Nov 2025) | IC substrate makers | BT developed 1976; continuous upgrades | Contract |
| OPE® substrate material | Low-dielectric substrate material for AI-server boards; FY2025 volume growth above plan; new manufacturing base under consideration | Server PCB/substrate makers | Ramping 2024–2026 | Contract |
| High-frequency circuit materials; thin laminates; fine-circuit materials | Next-gen package substrate materials | Substrate makers | Development / ramp | Contract |
| LE SHEET™ | Drilling entry/back-up sheet for PCB drilling | PCB makers | Long-established | Contract |
| AGELESS™ oxygen absorbers | Food freshness, pharmaceutical stability, metal anti-corrosion, cultural property protection; smaller, plastic-reduced and PFAS-compliant products | Food, pharma, museums | Since 1970s (not re-verified) | Contract/distributor |
| Food-loss technologies | Space-control and sterilization technology for meat and produce | Food distributors | Development | — |
| QOL Innovation Center Shirakawa | Oxygen absorber production and plant-factory vegetable cultivation (incl. wasabi cultivation R&D) | Food | Ongoing | — |
| Microphysiological System (MPS) devices | Organ-on-chip for drug discovery, co-developed with Ehime University | Pharma R&D | Development (FY2025 agreement) | — |
Financial Narrative
All figures consolidated, J-GAAP, ¥ million unless stated. FY2021 = year ended 31 Mar 2022 … FY2025 = year ended 31 Mar 2026. Sources: Yuho FY2024 and FY2025; tanshin; S&P Global Market Intelligence (via StockAnalysis) for line items not in the Yuho summary; ENVALITH cross-check. EBITDA = operating income + depreciation & amortization (analyst calculation; MGC's own medium-term-plan EBITDA definition is ordinary profit + interest expense + depreciation, which is higher).
Income statement
Diluted EPS equals basic (no dilutive securities per Yuho). FY2021 DPS of ¥80 per Yuho parent-company table.
Margins
Revenue CAGR: FY2021→FY2025 (4 years) +1.1% p.a.; FY2020→FY2025 (5 years, from ¥595,718m) +4.4% p.a. (analyst calculation). The five-year figure is flattered by the FY2021 post-COVID rebound and depressed by the FY2023 JSP deconsolidation.
Balance sheet (year-end)
Debt definitions: S&P-standardized total debt (including leases) is ¥224.3bn at Mar 2026; MGC's own Yuho states interest-bearing debt of ¥229.2bn. The discrepancy reflects classification differences. At Mar 2026 bonds outstanding were ¥55.0bn (all long-term, after redemption of ¥10.0bn) and long-term loans ¥102.4bn.
Ratios
ROE per Yuho; other ratios are analyst calculations on year-end balances. ROIC (company definition: (operating income – taxes + equity-method income) / invested capital): FY2024 6.4%, FY2025 3.2% (Yuho FY2025); earlier years not disclosed in the documents reviewed. S&P's standardized TTM ROIC (Jun 2026) is 7.18%, a different definition.
Quarterly cadence
Q1 FY2026 net sales, operating income and net income are rounded figures (¥223.7bn, ¥27.8bn, ¥18.3bn) from the Q1 tanshin summary; ordinary profit ¥29,187m is exact (Kabuyoho/IFIS).
Commentary on trends, inflections and drivers
Revenue. Sales peaked at ¥813.4bn in FY2023 and declined two years running. FY2024's –4.9% was largely mechanical (JSP deconsolidation from Q3 FY2023), while FY2025's –4.6% reflects genuine price pressure in methanol, PC and MXDA plus exit from the ortho-xylene chain, partly offset by electronic materials. Q1 FY2026 sales jumped 25.7% YoY on higher methanol prices (Middle East tensions), strong electronic materials and a weaker yen.
Operating profit. Operating income has been range-bound at ¥45–55bn for five years despite cumulative capex of c.¥362bn — the central problem the market is pricing. FY2021's ¥55.4bn high reflected the post-COVID chip and commodity boom; FY2023's ¥47.3bn low reflected the methanol/PC downturn. FY2025 operating income of ¥45.3bn was hit by MXDA competition and fixed-cost step-ups at the Taiwan semiconductor-chemicals site. Q1 FY2026 operating income of ¥27.8bn (+153.5%) is the strongest quarterly print in the period and annualizes above the full-year guidance of ¥71bn.
Ordinary profit and equity income. Equity-method income is the swing factor: it ranged from +¥17.5bn (FY2022) to –¥5.7bn (FY2023, when methanol affiliates suffered). FY2025's ¥1.5bn included an impairment at the Trinidad methanol affiliate. In Q1 FY2026, equity income fell to ¥0.5bn from ¥2.3bn because of reduced operation at the Saudi methanol producer amid regional tensions — a reminder that methanol price upside does not always flow through to MGC's affiliates.
Net income. The FY2025 loss of ¥40.3bn was driven by ¥78.4bn of impairments (Netherlands MXDA ¥50.2bn; Taiwan semiconductor-chemicals subsidiary c.¥10.6bn; China subsidiary; PC-related assets) and a ¥18.1bn tax charge on a pre-tax loss (non-deductibility of impairments). Extraordinary income of ¥14.7bn included ¥9.0bn of fixed-asset sale gains and ¥4.9bn of securities gains.
Balance sheet. Net debt rose from ¥5.6bn (Mar 2022) to ¥155.3bn (Mar 2026) as negative free cash flow combined with ¥86bn of dividends and ¥32bn of buybacks over five years. Net debt/EBITDA of 1.8x remains moderate and the equity ratio is 58%, but the trend — five consecutive years of negative FCF — is the clearest financial weakness. Inventory days lengthened from c.105 to c.131, adding working-capital drag.
Cash flow. Operating cash flow stepped up to c.¥74–75bn from FY2023, but capex of ¥77–85bn absorbed it. Capex guidance of ¥61bn for FY2026 and lower depreciation after impairments should allow FCF to turn positive in FY2026 for the first time in the period (analyst inference, not company guidance).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Business units (事業部) | Key products | Key consolidated / equity entities |
|---|---|---|---|
Green Energy & Chemicals (GEC) | C1 Chemicals; High Performance Products; Energy Resources & Environment; Life Science | Methanol, ammonia derivatives, DME, methylamines, MMA products, formalin, MXDA, aromatic aldehydes, polyols, MX-Nylon, special polyester, cyanate, polyimides, high-purity isophthalic acid, xylene isomers, natural gas, iodine, LNG power, geothermal, PQQ/SAMe | MGC Next, MGC Terminal, Toho Earthtech, MGC Specialty Chemicals Netherlands (MSCN), MGC Energy, MGC Woodchem; equity: Japan-Saudi Arabia Methanol, METOR, Brunei Methanol, Japan Trinidad Methanol, JSP, Yuzawa Geothermal, Appi Geothermal, Kokka Sangyo |
Functional Chemicals (FC) | Inorganic Chemicals; Synthetic Resins (engineering plastics); Optical Materials; Electronic Materials; Life & Hygiene Solutions | H2O2, persulfates, ultra-pure H2O2, HBC chemicals, Iupilon PC, Iupital POM, mPPE, PC sheet/film, Iupizeta EP, lens monomers, BT materials, OPE®, AGELESS | Taixing Ling Su (China), Samyoung Pure Chemicals (Korea, 51%), MGC Pure Chemicals America, MGC Pure Chemicals Singapore, Ju-Ling Precision Chemical (Taiwan), MGC Filsheet, Global Polyacetal, Thai Polyacetal, Korea Polyacetal, MGC Engineering Plastics (Shanghai), MGC Electrotechno, MGC Electrotechno (Thailand), MEP (75%), Thai Polycarbonate, Ageless (Thailand); equity: Korea Engineering Plastics, MGC Otsuka Chemical, Taifong PCB (Taiwan), Samyang Kasei |
Other | Purchased-goods trading not attributable to segments | — | — |
GEC | 350 | 22 | 32 |
FC | 490 | 65 | 65 |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
GEC net sales incl. intersegment (JPY Bn) | 323.1 | 286.9 |
GEC operating profit (JPY Bn) | 12.7 | 5.6 |
GEC ordinary profit (JPY Bn) | 20.5 | 3.8 |
GEC operating margin (%) | 3.9 | 2.0 |
FC net sales incl. intersegment (JPY Bn) | 444.1 | 448.3 |
FC operating profit (JPY Bn) | 41.3 | 43.8 |
FC ordinary profit (JPY Bn) | 43.9 | 49.1 |
FC operating margin (%) | 9.3 | 9.8 |
Other net sales (JPY Bn) | 19.1 | 14.8 |
Other operating profit (JPY Bn) | 1.1 | 1.3 |
Adjustments to sales (JPY Bn) | -12.9 | -11.8 |
Adjustments to operating profit (JPY Bn) | -4.4 | -5.5 |
Consolidated net sales (JPY Bn) | 773.5 | 738.2 |
Consolidated operating profit (JPY Bn) | 50.8 | 45.2 |
Revenue by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
GEC external sales (JPY Mn) | 313,392 | 277,904 |
FC external sales (JPY Mn) | 443,563 | 447,999 |
Other external sales (JPY Mn) | 16,474 | 12,339 |
GEC share of consolidated sales (%) | 40.5 | 37.6 |
FC share of consolidated sales (%) | 57.3 | 60.7 |
Other share of consolidated sales (%) | 2.1 | 1.7 |
Segment Assets & Liabilities and Results by Segment
| Metric | FY2024 | FY2025 |
|---|---|---|
GEC segment assets (JPY Mn) | 464,140 | 415,814 |
GEC depreciation (JPY Mn) | 13,751 | 13,217 |
GEC equity-method income (JPY Mn) | 8,035 | -807 |
GEC impairment loss (JPY Mn) | 258 | 56,145 |
GEC investment in equity-method affiliates (JPY Mn) | 140,689 | 143,348 |
Segment Revenue
| Item | GEC | FC | Other / Corporate | Total |
|---|---|---|---|---|
Capex FY2025 (JPY Mn) | 24,644 | 42,564 | 98 / 4,614 | 71,922 |
Capex plan FY2026 (JPY Mn) | 14,000 | 43,000 | 4,000 | 61,000 |
R&D expense FY2025 (JPY Mn) | 10,885 | 15,750 | — | 26,636 |
Consolidated employees 31 Mar 2026 | 2,632 | 5,090 | 106 / 491 | 8,319 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 705,656 | 781,211 | 813,417 | 773,591 | 738,243 |
Sales growth YoY (%) | 18.5 | 10.7 | 4.1 | -4.9 | -4.6 |
Gross profit (JPY Mn) | 162,586 | 168,180 | 173,190 | 164,293 | 161,362 |
SG&A (JPY Mn) | 107,225 | 119,149 | 125,852 | 113,442 | 116,068 |
Operating income (JPY Mn) | 55,360 | 49,030 | 47,337 | 50,851 | 45,293 |
Depreciation & amortization (JPY Mn) | 32,395 | 33,970 | 38,233 | 36,406 | 39,863 |
EBITDA (JPY Mn, OI + D&A) | 87,755 | 83,000 | 85,570 | 87,257 | 85,156 |
Equity-method income (JPY Mn) | 14,883 | 17,546 | -5,696 | 10,956 | 1,545 |
Ordinary profit (JPY Mn) | 74,152 | 69,764 | 46,040 | 60,316 | 51,947 |
Extraordinary income (JPY Mn) | 6,424 | 4,876 | 20,568 | 3,067 | 14,729 |
Extraordinary losses (JPY Mn) | 10,947 | 4,402 | 5,722 | 7,037 | 82,743 |
Pre-tax income (JPY Mn) | 69,628 | 70,239 | 60,887 | 56,347 | -16,065 |
Income taxes (JPY Mn) | 17,098 | 15,450 | 14,072 | 5,409 | 18,076 |
Net income attributable to owners (JPY Mn) | 48,295 | 49,085 | 38,818 | 45,544 | -40,318 |
EPS basic (JPY) | 232.15 | 239.08 | 190.97 | 228.93 | -207.04 |
EPS diluted (JPY) | 232.15 | 239.08 | 190.97 | 228.93 | -207.04 |
Dividend per share (JPY) | 80 | 80 | 80 | 95 | 100 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 23.0 | 21.5 | 21.3 | 21.2 | 21.9 |
Operating margin (%) | 7.8 | 6.3 | 5.8 | 6.6 | 6.1 |
EBITDA margin (%) | 12.4 | 10.6 | 10.5 | 11.3 | 11.5 |
Ordinary margin (%) | 10.5 | 8.9 | 5.7 | 7.8 | 7.0 |
Net margin (%) | 6.8 | 6.3 | 4.8 | 5.9 | -5.5 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (JPY Mn) | 928,651 | 1,029,317 | 1,068,010 | 1,119,688 | 1,113,040 |
Cash & deposits (JPY Mn) | 102,049 | 108,378 | 71,447 | 68,246 | 68,966 |
Cash & cash equivalents per CF statement (JPY Mn) | 92,257 | 101,185 | 65,397 | 56,985 | 59,096 |
Short-term debt incl. current bonds (JPY Mn) | 38,925 | 47,913 | 51,818 | 85,617 | 64,240 |
Long-term debt: bonds + LT loans (JPY Mn) | 66,621 | 94,680 | 99,671 | 114,441 | 157,439 |
Total debt incl. leases (JPY Mn) | 107,648 | 146,943 | 155,001 | 202,976 | 224,267 |
Net debt (JPY Mn) | 5,593 | 38,472 | 83,554 | 134,730 | 155,301 |
Total net assets (JPY Mn) | 630,887 | 671,249 | 684,832 | 697,375 | 679,550 |
Shareholders' equity excl. minorities (JPY Mn) | 568,766 | 607,613 | 657,745 | 668,222 | 646,417 |
Goodwill (JPY Mn) | 4,811 | 4,425 | 16,868 | 15,310 | 13,751 |
Other intangibles (JPY Mn) | 6,479 | 7,555 | 8,003 | 9,685 | 9,794 |
Inventories (JPY Mn) | 155,669 | 178,142 | 200,529 | 207,526 | 206,983 |
Working capital (JPY Mn) | 253,241 | 262,807 | 221,668 | 185,339 | 220,667 |
Equity ratio (%) | 61.25 | 59.03 | 61.59 | 59.68 | 58.08 |
Book value per share (JPY) | 2,733.86 | 2,970.07 | 3,284.96 | 3,431.90 | 3,319.36 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | 52,090 | 55,222 | 73,473 | 75,440 | 74,726 |
Capital expenditure (JPY Mn) | 56,347 | 62,721 | 80,815 | 85,366 | 76,731 |
Free cash flow (JPY Mn) | -4,257 | -7,499 | -7,342 | -9,926 | -2,005 |
Investing cash flow (JPY Mn) | -64,954 | -64,071 | -76,172 | -90,994 | -61,311 |
Financing cash flow (JPY Mn) | -3,666 | 7,996 | -40,689 | 4,707 | -14,364 |
Dividends paid (JPY Mn) | 16,642 | 15,464 | 16,367 | 17,021 | 19,472 |
Share buybacks (JPY Mn) | 5 | 7,083 | 10,005 | 15,006 | 7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 8.84 | 8.35 | 6.14 | 6.87 | -6.13 |
ROA (NI / avg assets, %) | 5.2 | 4.8 | 3.6 | 4.1 | -3.6 |
Current ratio (x) | 2.27 | 2.19 | 1.92 | 1.67 | 1.96 |
Total debt / net assets (x) | 0.17 | 0.22 | 0.23 | 0.29 | 0.33 |
Net debt / EBITDA (x) | 0.06 | 0.46 | 0.98 | 1.54 | 1.82 |
Interest coverage, OI / interest expense (x) | 64.5 | 28.1 | 18.5 | 21.4 | 16.8 |
Asset turnover, sales / avg assets (x) | 0.80 | 0.80 | 0.78 | 0.71 | 0.66 |
Days sales outstanding (days) | 90.6 | 82.2 | 74.0 | 74.1 | 73.4 |
Days inventory outstanding (days) | 104.6 | 106.1 | 114.3 | 124.3 | 131.0 |
Days payables outstanding (days) | 62.1 | 52.6 | 62.2 | 61.8 | 58.2 |
Cash conversion cycle (days) | 133.1 | 135.7 | 126.2 | 136.6 | 146.2 |
Income Statement
| Metric | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 |
|---|---|---|---|---|---|
Net sales (JPY Mn) | 177,977 | 183,701 | 187,783 | 188,782 | 223,700 |
Operating income (JPY Mn) | 10,982 | 14,163 | 12,659 | 7,489 | 27,800 |
Ordinary profit (JPY Mn) | 13,830 | 17,650 | 16,691 | 3,776 | 29,187 |
Net income (JPY Mn) | 8,405 | -36,344 | 1,779 | -14,158 | 18,300 |
Region Overview
| Region | Main consolidated production assets | Segment |
|---|---|---|
Japan | Niigata, Mizushima, Yokkaichi, Yamakita, Kashima, Naniwa plants; MGC Electrotechno Shin-Shirakawa; Toho Earthtech; MGC Ageless Shirakawa | Both |
Thailand | MGC Electrotechno (Thailand) (BT; doubled capacity Nov 2025), Thai Polyacetal, Thai Polycarbonate, Ageless (Thailand) | FC |
Korea | Samyoung Pure Chemicals (ultra-pure H2O2), Korea Polyacetal | FC |
China | MGC Engineering Plastics (Shanghai) (PC), Taixing Ling Su (electronic chemicals) | FC |
Taiwan | Ju-Ling Precision Chemical, Taichung (semiconductor chemicals; impaired FY2025) | FC |
United States | MGC Pure Chemicals America: Arizona, Oregon, Texas | FC |
Singapore | MGC Pure Chemicals Singapore | FC |
Netherlands | MSCN Rotterdam (MXDA; construction discontinued, removal by end-2029) | GEC |
Equity affiliates | Saudi Arabia, Brunei, Venezuela, Trinidad & Tobago (methanol); Indonesia (H2O2); Korea (KEP); Taiwan (Taifong PCB) | Both |
Capital Markets Data (JPY) and Valuation Multiples (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Fiscal-year high (JPY) | 2,823 | 2,234 | 2,685.5 | 3,370 | 5,446 |
Fiscal-year low (JPY) | 1,842 | 1,766 | 1,899 | 2,131 | 1918 |
P/E at fiscal year-end (x) | 8.96 | 8.21 | 13.56 | 10.16 | 0 |
Total shareholder return, 5-yr cumulative index (%) | 79.6 | 78.2 | 104.3 | 98.0 | 148.5 |
TOPIX incl. dividends, same basis (%) | 102.0 | 107.9 | 152.5 | 150.2 | 202.2 |
Valuation Multiples
| Multiple | MGC | Source |
|---|---|---|
Market cap | ¥748.8bn | S&P/StockAnalysis |
EV | ¥934.1bn | S&P/StockAnalysis |
P/E (trailing) | n/m (loss) | — |
P/E (forward, consensus) | 15.5x | S&P/StockAnalysis |
P/E (company forecast) | 13.3–13.4x | Kabuyoho/Monex |
EV/EBITDA (TTM) | 9.25x | S&P/StockAnalysis |
EV/Sales (TTM) | 1.19x | S&P/StockAnalysis |
P/B | 1.07–1.11x | S&P; Kabuyoho |
Dividend yield | 2.82–2.93% | S&P; Kabuyoho |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Dividend per share (JPY) | 80 | 80 | 80 | 95 | 100 | 110 |
Dividends paid (JPY Mn) | 16,642 | 15,464 | 16,367 | 17,021 | 19,472 | 21,400 |
Resolution Date Details
| Resolution date | Max shares | Max value | Period | Executed | Cancellation |
|---|---|---|---|---|---|
8 Nov 2023 | 5,000,000 (2.44%) | ¥10.0bn | 9 Nov 2023 – 31 Jan 2024 | Completed | 5,000,000 shares cancelled 31 Jan 2024 |
8 Nov 2024 | 5,600,000 (2.80%) | ¥15.0bn | 11 Nov 2024 – 24 Mar 2025 | 5,552,600 shares, ¥14.9998bn | Cancelled 31 Mar 2025 |
Capital Instruments
| Instrument | Amount (JPY Mn) | Maturity bucket |
|---|---|---|
Short-term borrowings | 64,240 | < 1 year |
Current portion of bonds | 0 | < 1 year (¥10bn redeemed in FY2025) |
Bonds | 55,000 | — |
Long-term borrowings | 102,439 | — |
Lease obligations | 2,588 | Mixed |
Analyst Conclusions
Management guidance (FY2026, revised 7 Aug 2026)
| Metric | Original guide (13 May 2026) | Revised guide (7 Aug 2026) | YoY vs FY2025 (revised) |
|---|---|---|---|
| Net sales (¥bn) | 840 | 860 | +16.5% |
| Operating profit (¥bn) | 59 | 71 | +56.8% |
| Ordinary profit (¥bn) | 66 | 79 | +52.1% |
| Net income (¥bn) | 46 | 55 | turnaround from –40.3 |
| H1 ordinary profit (¥bn) | — | 46 | — |
| DPS (¥) | 110 | 110 | +10 |
| Capex (¥bn) | 61 | — | –15% |
Q1 FY2026 delivered 36.9% of full-year ordinary profit guidance. Management noted Middle East effects were limited except at the Saudi site and that cost increases are being passed through, while some product markets remain unstable (Q1 presentation summary).
Consensus growth expectations
Consensus FY2026 ordinary profit of c.¥79.3bn sits essentially on company guidance; consensus 3-year revenue CAGR c.6.7% (S&P). Simply Wall St previously cited c.4.6% p.a. revenue growth (May 2025).
Bull case
-
Earnings inflection is real: Q1 FY2026 OP of ¥27.8bn (+153.5%) annualizes well above the ¥71bn guide; FC segment profit already rose in a weak FY2025, and AI-server OPE® demand is running ahead of plan.
-
Clean-up removes drag: ¥78.4bn of impairments, the MSCN exit and the Kashima closure cut depreciation and loss-making exposure; management cites c.¥15bn of reform benefits. FY2026 NI of ¥55bn implies ROE of c.8.5%, close to the ≥9% target.
-
Valuation and returns: at c.1.1x book and a c.2.8% yield with a progressive dividend, the stock offers downside support; consensus targets imply c.40% upside.
Bear case
-
Execution credibility: two major overseas projects (MSCN, Taiwan chemicals) were impaired within a year; ROIC was 3.2% in FY2025; FCF has been negative for five consecutive years, and net debt rose to ¥155bn.
-
Plan miss: even after the upgrade, FY2026 OP guidance (¥71bn) is ¥14bn short of the ¥85bn plan, and the 10% margin target looks out of reach; the plan's ¥135/$ assumption flatters exporters.
-
Commodity and geopolitical tail risk: equity income collapsed to ¥0.5bn in Q1 FY2026 despite higher methanol prices because of the Saudi outage; Venezuela and Trinidad remain impairment candidates; Chinese overcapacity continues to pressure MXDA, PC and POM.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| 10 Nov 2026 | Q2 FY2026 results — delivery vs ¥46bn H1 ordinary guide; any further guidance upgrade |
| H2 FY2026 | OPE® capacity decision (new base); BT utilization in Thailand |
| H2 FY2026 | Xylene-chain restructuring decision following MSCN exit |
| Ongoing | Saudi methanol affiliate operating rate; methanol price trajectory |
| Ongoing | Taiwan/US semiconductor-chemical utilization and fixed-cost absorption |
| Feb 2027 | Q3 FY2026 results |
| May 2027 | FY2026 results; launch of the next medium-term plan (post-Grow UP 2026) with new ROIC targets and capital-allocation framework |
| Any time | Resumption of buybacks (none in FY2025) as FCF turns positive |
| Any time | Further cross-shareholding disposals |
Analyst verdict
Mitsubishi Gas Chemical enters the final year of Grow UP 2026 with a clearer identity than at any point in the past decade. The FY2025 loss was painful but largely non-cash and concentrated in assets that were never central to the company's future: a late-cycle European MXDA plant, an over-built Taiwan chemical site, a sub-scale domestic polycarbonate line and an exposed methanol affiliate. What remains is a functional-materials franchise that generated nearly all of FY2025's segment ordinary profit and that sits squarely in the path of AI-server and advanced-packaging demand, plus a methanol business that is volatile but strategically optioned on decarbonized fuels.
The first quarter of FY2026 validated the recovery thesis faster than consensus expected, and the balance sheet — 58% equity ratio, net debt/EBITDA below 2x — absorbs the write-downs without stress. Valuation at roughly book value and around 13–15x forward earnings does not demand heroic assumptions.
The case against is not about solvency but about stewardship. Five consecutive years of negative free cash flow, an operating profit line stuck between ¥45bn and ¥55bn despite heavy investment, and ROIC far below the cost of capital mean that the market's long-standing discount is earned. The next medium-term plan, due around May 2027, is therefore the pivotal event: investors will want explicit capital-allocation discipline (hurdle rates, capex ceilings, buyback commitments), a decision on the residual xylene chain, and a credible path to the 10% operating margin the current plan will miss.
On balance, we view MGC as a recovery-with-quality-core story whose near-term earnings momentum is strong but whose re-rating depends on proving that FY2025 marked the end, not a pause, in value-destructive capex. Positive near-term skew; conviction contingent on H2 FY2026 delivery and the shape of the next plan.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Born (age at Oct 2026) | MGC tenure / key prior roles | Shares held |
|---|---|---|---|---|
Masashi Fujii | Representative Director, Chairman; Board Chair; chairs Compensation & Nomination Committee | 10 Mar 1959 (67) | Joined 1981; organic chemicals business head; Natural Gas Chemicals Company President; Director 2015; President Apr 2019–Mar 2025; Chairman since Apr 2025 | 51k |
Yoshinori Isahaya | Representative Director, President & CEO | 18 Apr 1965 (61) | Joined 1991; Tokyo Research Lab head (2019); executive officer, corporate planning (2020–21); managing executive officer, R&D and IP (2023); President since Apr 2025 | 21k |
Motoyasu Kitagawa | Director, Senior Managing Executive Officer — internal control & risk, HR/GA, finance & accounting, CSR/IR (de facto CFO) | 2 Apr 1963 (63) | Joined 1986; President, MGC America (2014); corporate planning head (2019) | 26k |
Ko Mouto (毛戸耕) | Director, Managing Executive Officer — production technology, EHS & QA, raw materials & logistics | 5 Feb 1964 (62) | Joined 1988; Mizushima plant manager (2019); R&D (2021) | 22k |
Tomoyuki Azuma | Director, Managing Executive Officer — R&D and IP | 21 Jun 1965 (61) | Joined 1989; Electronic Materials Division head (2019–2025) | 12k |
Chika Kobayashi | Director, Managing Executive Officer — compliance, corporate planning, internal audit, IT | 25 Aug 1966 (60) | Joined 1990; accounting group manager; corporate planning head (2023) | 12k |
Yasushi Manabe | Outside Director (independent) | 15 Dec 1956 (69) | Ex-Hitachi executive officer/CMO; outside director at Nichias | 2k |
Kazue Kurihara | Outside Director (independent) | 24 Jan 1951 (75) | Professor emerita, Tohoku University (surface chemistry); outside director at Hamamatsu Photonics | 1k |
Chi Sato | Outside Director (independent) | 8 Aug 1954 (72) | Career diplomat; ambassador to UNESCO and Hungary | — |
Mihoko Manabe | Outside Director (independent; foreign national) | 3 Nov 1958 (67) | Moody's (1988–2023), Managing Director at Moody's Japan; outside director at Torii Pharmaceutical | — |
Board of Directors — Masato Inari
| Name | Role | Background |
|---|---|---|
Masato Inari | Full-time Audit & Supervisory Board Member | Former Representative Director/Senior MEO; ex-Niigata plant head |
Nobuhisa Ariyoshi | Full-time A&SB Member | Former Representative Director/Senior MEO (finance, HR, risk) |
Mayako Perez Takahashi | Full-time Outside A&SB Member | Audit firm (Deloitte Tohmatsu, KPMG AZSA), JICA, ORIX |
Tsuneaki Tejima | Outside A&SB Member | Ex-Nippon Life director; President, NLI Research Institute |
Tsuyoshi Watanabe | Outside full-time member — resigned at June 2026 AGM | Ex-MUFG Bank, Nidec |
Directors' Remuneration
| Category | Total (JPY Mn) | Base (JPY Mn) | Performance-linked (JPY Mn) | Restricted stock (JPY Mn) | Headcount |
|---|---|---|---|---|---|
Directors (excl. outside) | 518 | 326 | 148 | 42 | 10 |
A&SB members (excl. outside) | 55 | 55 | — | — | 3 |
Outside officers | 86 | 86 | — | — | 9 |
Total | 660 | 468 | 148 | 42 | 22 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Apr 2025 | Isahaya appointed President; Fujii to Chairman; Kurai steps down from representative role (director until June 2025) | Planned succession announced 3 Feb 2025 |
Jun 2025 AGM | Outside directors Chi Sato and Mihoko Manabe join; Haruko Hirose and Toru Suzuki leave; Ariyoshi and Perez Takahashi join A&SB | Board refresh |
Apr 2026 | Azuma's portfolio retitled R&D and IP | Organizational |
Jun 2026 AGM | Board reduced to 10; Yamaguchi and Akase leave board; Watanabe resigns from A&SB | Governance streamlining after FY2025 loss |
Major Shareholders
| Rank | Holder | Shares (000) | % |
|---|---|---|---|
| 1 | The Master Trust Bank of Japan (trust account) | 21,516 | 11.05 |
| 2 | Custody Bank of Japan (trust account) | 14,717 | 7.56 |
| 3 | Meiji Yasuda Life Insurance | 8,797 | 4.52 |
| 4 | State Street Bank and Trust Co. 505001 | 6,593 | 3.39 |
| 5 | Nippon Life Insurance | 5,858 | 3.01 |
| 6 | National Mutual Insurance Federation of Agricultural Cooperatives (Zenkyoren) | 5,775 | 2.97 |
| 7 | Norinchukin Bank | 5,026 | 2.58 |
| 8 | JPMorgan Securities Japan | 4,372 | 2.25 |
| 9 | MSIP Client Securities | 3,594 | 1.85 |
| 10 | Morgan Stanley MUFG Securities | 3,136 | 1.61 |
| — | Top 10 total | 79,389 | 40.77 |
Competitive Landscape
Competitors by Segment
| MGC business | Named competitors | Relative positioning of MGC |
|---|---|---|
BT / IC-package substrate materials | Resonac (ex-Hitachi Chemical/Showa Denko Materials), Panasonic Industry (MEGTRON series, high-speed laminates), Doosan Electro-Materials, Sumitomo Bakelite, Elite Material Co. (EMC), ITEQ, Taiwan Union Technology | Category originator in BT; strong position in memory/logic package substrates. |
OPE® / high-frequency server materials | Panasonic Industry, EMC, Doosan, Resonac | Fast-growing challenger; volumes ahead of plan |
Ultra-pure H2O2 and wet process chemicals | Solvay, Evonik, Arkema (H2O2); Kanto Chemical, Mitsubishi Chemical, Dongwoo Fine-Chem, Entegris (formulated chemistries) | Global multi-site footprint (US, Asia); Taiwan expansion under-earning |
Methanol | Methanex, SABIC (partner), Proman, Chinese coal-to-methanol producers | Mid-size equity-based producer; differentiated by technology licensing and Carbopath |
MXDA and derivatives | Chinese producers (unnamed in MGC filings) | Historic technology leader losing price leadership |
Polycarbonate | Covestro, SABIC, Teijin, Mitsubishi Chemical (partner in MEP), LG Chem, Lotte Chemical, Wanhua | Sub-scale in commodity PC; retreating (Kashima closure) |
POM | Celanese (partner in KEP), Polyplastics, Asahi Kasei, Chinese producers | Mid-tier |
Optical resin polymers / lens monomers | Mitsui Chemicals (MR lens monomers, APEL), Teijin, Osaka Gas Chemicals (OKP), Zeon (COP) | Strong in high-index smartphone camera lens polymers |
Oxygen absorbers | Multisorb (Filtration Group), Clariant (CSP), various Asian producers | AGELESS is a pioneer brand |
Peer Comparison FY2026
| Company | Revenue (JPY Bn) | Operating margin (%) | ROE (%) | Equity ratio (%) | Fiscal year basis |
|---|---|---|---|---|---|
Mitsubishi Gas Chemical | 773.6 | 6.6 | 6.9 | 59.7 | FY ended Mar 2025 |
Mitsubishi Gas Chemical | 738.2 | 6.1 | -6.1 | 58.1 | FY ended Mar 2026 |
Mitsubishi Chemical Group | 3,700 | 0.8 | 0.7 | 30.0 | Latest per EDINET DB comparison |
Asahi Kasei | 3,070 | 7.5 | 8.0 | 50.5 | Latest per EDINET DB comparison |
Shin-Etsu Chemical | 2,570 | 24.7 | 10.4 | 78.7 | Latest per EDINET DB comparison |
Sumitomo Chemical | 2,330 | 6.5 | 6.4 | 29.6 | Latest per EDINET DB comparison |
Japanese chemicals industry median (157 cos.) | — | 6.9 | 6.6 | 64.6 | EDINET DB |
Recent Developments
--



